HLS.TO Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 21:05):

Stats
Tagesvolumen	700.00
Durchschnittsvolumen	9 848.00
Marktkapitalisierung	148.43M
EPS	$-0.170 ( 2024-03-14 )
Nächstes Ertragsdatum	( $-0.250 ) 2024-05-08
Last Dividend	$0.0500 ( 2023-04-27 )
Next Dividend	$0 ( N/A )
P/E	-3.97
ATR14	$0 (0.00%)

HLS THERAPEUTICS INC Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

HLS THERAPEUTICS INC Finanzdaten

Annual	2023
Umsatz:	$63.07M
Bruttogewinn:	$55.45M (87.91 %)
EPS:	$-0.850

FY	2023
Umsatz:	$63.07M
Bruttogewinn:	$55.45M (87.91 %)
EPS:	$-0.850

FY	2022
Umsatz:	$61.47M
Bruttogewinn:	$56.49M (91.90 %)
EPS:	$-0.730

FY	2021
Umsatz:	$60.01M
Bruttogewinn:	$56.04M (93.38 %)
EPS:	$-0.410

Financial Reports:

No articles found.

HLS THERAPEUTICS INC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.0500 (N/A)	$0.0500 (N/A)	$0.0500 (N/A)	$0.0500 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

HLS THERAPEUTICS INC Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.14 - low (4.63%) | Divividend Growth Potential Score: 1.423 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0500	2019-01-30
Last Dividend	$0.0500	2023-04-27
Next Dividend	$0	N/A
Payout Date	2023-06-15
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	$0.900	--
Avg. Dividend % Per Year	0.75%	--
Score	2.66	--
Div. Sustainability Score	3.14
Div.Growth Potential Score	1.423
Div. Directional Score	2.28	--

Next Divdend (Est)
(2024-07-01)

$0.0509 Estimate 10.00 %

Dividend Stability

0.40 Below Average

Dividend Score

2.66

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2019	$0.200	1.43%
2020	$0.200	0.81%
2021	$0.200	1.18%
2022	$0.200	1.36%
2023	$0.100	0.99%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for TSX

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
ZRE.TO	Dividend Knight	2023-08-29	Monthly	15	2.60%
TLF.TO	Dividend King	2023-08-30	Monthly	13	3.15%
L-PB.TO	Dividend King	2023-09-14	Quarterly	10	3.24%
CMAR.TO	Dividend Knight	2023-09-22	Monthly	5	2.05%
XLB.TO	Dividend Knight	2023-08-25	Monthly	19	1.89%
PZA.TO	Dividend Royal	2023-09-28	Monthly	20	4.10%
FM.TO	Dividend Junior	2023-08-25	Semi-Annually	20	0.32%
ABST.TO	Dividend Knight	2023-05-10	Quarterly	12	1.37%
VBAL.TO	Dividend Junior	2023-07-05	Quarterly	7	1.11%
MR-UN.TO	Dividend King	2023-09-28	Monthly	12	4.52%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.436	1.500	-8.73	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.132	1.200	-4.39	-5.27	[0 - 0.3]
returnOnEquityTTM	-0.256	1.500	-3.96	-5.94	[0.1 - 1]
payoutRatioTTM	-0.0871	-1.000	-0.871	0.871	[0 - 1]
currentRatioTTM	1.652	0.800	6.74	5.39	[1 - 3]
quickRatioTTM	1.223	0.800	7.51	6.01	[0.8 - 2.5]
cashRatioTTM	0.823	1.500	6.54	9.81	[0.2 - 2]
debtRatioTTM	0.419	-1.500	3.01	-4.52	[0 - 0.6]
interestCoverageTTM	-1.143	1.000	-1.534	-1.534	[3 - 30]
operatingCashFlowPerShareTTM	0.501	2.00	9.83	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.499	2.00	9.75	10.00	[0 - 20]
debtEquityRatioTTM	0.897	-1.500	6.41	-9.62	[0 - 2.5]
grossProfitMarginTTM	0.879	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.159	1.000	-5.17	-5.17	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.180	1.000	-0.110	-0.110	[0.2 - 2]
assetTurnoverTTM	0.302	0.800	-1.322	-1.058	[0.5 - 2]
Total Score				3.14

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.90	1.000	-0.495	0	[1 - 100]
returnOnEquityTTM	-0.256	2.50	-2.54	-5.94	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.499	2.00	9.83	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.501	2.00	9.83	10.00	[0 - 30]
payoutRatioTTM	-0.0871	1.500	-0.871	0.871	[0 - 1]
pegRatioTTM	0.115	1.500	-2.56	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.250	1.000	6.24	0	[0.1 - 0.5]
Total Score				1.423

HLS THERAPEUTICS INC

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.